MedTrace Logo

The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women

NCT01290432 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-05-25

No results posted yet for this study

Summary

Dr. Roseff and his colleagues are conducting a study to evaluate the effectiveness of a novel substance (Inofolic Plus®) in improving oocyte (egg) parameters in subfertile female patients, as measured through Anti-Mullerian Hormone (AMH) blood levels.

Conditions

  • Infertility, Female

Interventions

DIETARY_SUPPLEMENT

Inofolic Plus

Inofolic Plus contains folic acid and myoinositol and melatonin

Sponsors & Collaborators

  • Lo.Li. Pharma, Ltd.

    collaborator UNKNOWN

  • Palm Beach Center for Reproductive Medicine

    lead OTHER

Principal Investigators

  • Scott Roseff, MD · Palm Beach Center for Reproductive Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290432 on ClinicalTrials.gov